F. Hoffmann-La Roche Ltd - Company Profile
Powered by
All the data and insights you need on F. Hoffmann-La Roche Ltd in one report.
- Save hours of research time and resources with
our up-to-date F. Hoffmann-La Roche Ltd Strategy Report
- Understand F. Hoffmann-La Roche Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreF. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Roche is headquartered in Basel, Switzerland.
F. Hoffmann-La Roche Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pharmaceuticals for: | Accu-Chek |
Anemia | AmpliChip |
Bone Diseases | Accutrend |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In June, the company received approval from the European Commission for Alecensa (alectinib) monotherapy, as adjuvant treatment following tumor resection for adult patients with anaplastic lymphoma kinase -positive non-small cell lung cancer at high-risk of recurrence. |
2024 | Contracts/Agreements | In May, the company announced the enhancement of its partnership with Enable Injections to evolve and apply Enable’s expertise and enFuse delivery technology. |
2024 | Regulatory Approval | In May, the company received approval from the FDA for its human papillomavirus self-collection solution in the US. |
Competitor Comparison
Key Parameters | F. Hoffmann-La Roche Ltd | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
---|---|---|---|---|---|
Headquarters | Switzerland | United States of America | United States of America | United States of America | United States of America |
City | Basel | New Brunswick | Rahway | New York | North Chicago |
State/Province | - | New Jersey | New Jersey | New York | Illinois |
No. of Employees | 103,605 | 131,900 | 72,000 | 88,000 | 50,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
![Image for loader](https://assets.globaldata.com/gdcom/assets/img/ajax-loadernew.gif)
Net Income Growth
![Image for loader](https://assets.globaldata.com/gdcom/assets/img/ajax-loadernew.gif)
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Severin Schwan | Chairman | Executive Board | 2023 | 57 |
Thomas Schinecker | Chief Executive Officer | Senior Management | 2023 | 49 |
Alan Hippe | Chief Information Officer; Chief Financial Officer | Senior Management | 2011 | 57 |
Cristina A. Wilbur | Chief People Officer | Senior Management | 2016 | 57 |
Levi Garraway | Chief Medical Officer; Head - Global Product Development | Senior Management | 2023 | 55 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer